Hyderabd/Mumbai, India – Himal P. Desai has recently been promoted to Executive Vice President – Supply Chain & IT at Sekhmet Pharmaventures, marking a significant milestone in his career. This new role, builds on his extensive experience in supply chain management and strategic IT implementations within the pharmaceutical sector.
“I’m happy to share that I’m starting a new position as Executive Vice President – Supply Chain & IT at Sekhmet Pharmaventures!” Desai announced, underscoring his readiness to lead the company’s ambitious objectives in these crucial areas.
Desai’s career at Sekhmet Pharmaventures has been dynamic and fast-paced. Within just 11 months at the company, he quickly advanced from Vice President to Executive Vice President, initially focusing solely on Supply Chain before taking on additional IT responsibilities. His tenure at the company has already seen significant improvements in operational efficiencies and strategic planning.
Prior to his current role at Sekhmet Pharmaventures, Desai was Vice President of Supply Chain at Virchow Biotech, where he led procurement, logistics, and warehousing initiatives across five units involved in diverse product lines, including biologics, vaccines, and medical devices. His efforts there included major reorganizations of supply chain processes, which enhanced the company’s agility and reduced costs significantly.
Before joining Virchow Biotech, Desai managed the supply chain for KIMS Hospitals, overseeing operations across nine hospitals and leading a large team to streamline processes and improve customer satisfaction. His earlier roles at global firms like Novartis and Piramal Enterprises allowed him to develop and implement strategic supply chain initiatives that significantly boosted operational efficiencies and cost savings.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
About Sekhmet Pharmaventures:
Sekhmet Pharmaventures Pvt. Ltd., the Indian arm of Gamot API Pte Ltd. based in Singapore, represents a strategic initiative by major investment entities including PAG, CX Partners, and Samara Capital. The company focuses on acquiring stakes in fast-growing pharmaceutical companies, enhancing India’s role in the global supply chain, especially in the production of Active Pharmaceutical Ingredients (APIs) and formulations. With initial investments in Chennai-based Anjan Drug Pvt. Ltd. and the Optimus Drugs Group, Sekhmet Pharmaventures is poised to capitalize on changing geopolitical dynamics and India’s burgeoning pharmaceutical sector. The company’s strategy includes expanding its manufacturing facilities to support both CMO (Contract Manufacturing Organization) activities and proprietary production, ensuring a robust supply chain that meets global market demands.
